Zentalis Pharmaceuticals ZNTL 深 沪
等待开盘 10-04 09:30:00 美东时间
1.61
-0.050
-3.01%
华盛通- 最 高1.69
- 今 开1.67
- 成交量 73.97万股
- 最 低 1.60
- 昨 收 1.66
- 总市值 1.16亿
- 52周最高 4.44
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.01
- 委 比 28.97%
- 总股本 7213.55万
- 历史最高 87.19
- 量 比 1.06
- 振 幅 5.42%
- 历史最低 1.01
- 每 手 1
- 风险率 0.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ZenaTech Signs Offer to Acquire a Warehouse and Inventory Management Company with Established Long-Term US Defense Government Contracts, Accelerating DaaS Expansion on the East Coast
ZenaTech, a company specializing in AI drones and logistics solutions, has signed an offer to acquire a Southeast US-based warehouse and inventory management services company serving the US Department of Defense. This acquisition aims to enhance ZenaTech's capacity to provide Drone as a Service (DaaS) to government and defense agencies in the East Coast region. The deal will also strengthen the deployment of its IQ Nano indoor drone, designed for...
09-09 12:30
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Zentalis Pharmaceuticals announced that its management team will participate in three upcoming investor conferences: the 2025 Wells Fargo Healthcare Conference in Boston on September 4, 2025, featuring a fireside chat; the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8, 2025, with a company presentation; and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on September 9, 2025, including...
08-28 20:15
Zentalis Pharmaceuticals Announces New Chief Legal Officer
An update from Zentalis Pharmaceuticals ( ($ZNTL) ) is now available. On August...
08-27 04:30
Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary
Zentalis Pharmaceuticals appoints James B. Bucher as Chief Legal Officer and Corporate Secretary, effective September 18, 2025. Bucher, with over 30 years of experience in life sciences legal matters, including strategic transactions and corporate governance, succeeds Andrea Paul, who is departing to join an international law firm. Bucher previously led the acquisition of Harpoon Therapeutics by Merck and has held senior legal roles at Eliem Ther...
08-26 20:05
Wells Fargo Maintains Equal-Weight on Zentalis Pharma, Lowers Price Target to $5
Wells Fargo analyst Derek Archila maintains Zentalis Pharma (NASDAQ:ZNTL) with a Equal-Weight and lowers the price target from $6 to $5.
08-07 22:38
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress
Zentalis Pharmaceuticals reported positive progress in its DENALI Phase 2 trial for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer (PROC), with topline data expected by end-2026. The company has $303.4 million in cash, supporting operations into late 2027. Azenosertib demonstrated anti-tumor activity and is being evaluated for accelerated approval. R&D expenses decreased by $20.8 million, and G&A expenses decreased by $8.3 mi...
08-06 20:05
Responding to the White House AI Action Plan, ZenaTech’s ZenaDrone Launches Zena AI, Inc., a Specialized AI Development Center for US Defense and Homeland Security Applications
VANCOUVER, BC – ZenaTech, Inc. announced the formation of Zena AI, Inc., an AI Development Center under its ZenaDrone US subsidiary. Zena AI will focus on developing advanced AI software solutions for the US Department of Defense and Homeland Security, in response to the White House’s AI Action Plan and related Executive Orders released on July 23. The initiative aims to accelerate the development of American-made AI systems and boost global expo...
07-29 12:15
ZenaTech Poised to Benefit from Historic US Defense Spending─$33 Billion for Drone and Autonomy Investments in ‘One Big Beautiful Bill’
ZenaTech anticipates significant benefits from the recently passed One Big Beautiful Bill Act, which allocates $33 billion for advanced drones and defense modernization. The bill includes $150 billion in defense spending and restores R&D incentives, enhancing ZenaTech's financial position. ZenaTech, a leader in AI drones and DaaS, plans to leverage these opportunities to grow its defense and government agency partnerships. The company's products,...
07-08 12:00
ZenaTech Signs Offer to Acquire North Carolina Land Surveying Company to Expand State Operations and Government Customers
ZenaTech Inc. has agreed to acquire a North Carolina-based land surveying company with a strong government client base. This strategic move aims to enhance regional market penetration and growth in the U.S. Southeast while supporting its Drone as a Service (DaaS) expansion. The acquisition focuses on integrating AI-powered drones into land survey workflows for improved efficiency. ZenaTech has completed five acquisitions and plans 20 more within ...
06-26 12:00
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals granted 137,400 non-qualified stock options to four new employees on June 2, 2025, under its 2022 Inducement Plan. The options have an exercise price of $1.28 per share, vest over four years, and are contingent on continued employment. The company focuses on developing a first-in-class WEE1 inhibitor for ovarian cancer and other cancers.
06-02 21:00
